Meeting Details - The second extraordinary general meeting of shareholders for 2025 will be held on September 10, 2025, at 14:30 [2] - Network voting will be available on the Shenzhen Stock Exchange from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on the same day [2] - All shareholders registered by 15:00 on the record date are entitled to attend and vote at the meeting [2][5] Voting Procedures - Voting will be conducted through non-cumulative voting proposals, requiring more than two-thirds approval from the total voting shares [4] - Shareholders can participate in network voting via the Shenzhen Stock Exchange trading system and the internet voting system [5][6] - Specific procedures for network voting and registration for both corporate and individual shareholders are outlined [5][6] Registration Requirements - Corporate shareholders must provide a range of documents including a business license and a power of attorney if represented [5] - Individual shareholders need to present their ID and shareholder account card for registration [5] - Shareholders participating in margin trading must follow specific registration guidelines [5]

Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [2][3] - The registered capital of the company is RMB 855,942,012 [3][7] - The company aims to integrate pharmaceutical production, scientific research, and trade [4] Company Structure - The company has a legal representative who is the chairman of the board, and the legal representative's appointment and changes are governed by the same rules as the chairman [3][4] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3][4] Share Issuance and Capital Management - The company has issued a total of 855,942,012 shares, all of which are ordinary shares [7] - The company cannot provide financial assistance for others to acquire its shares, except under specific conditions approved by the shareholders' meeting [7][8] - The company can reduce its registered capital following legal procedures [8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, supervise the company's operations, and request information [15][34] - Shareholders must comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [40][41] Governance and Decision-Making - The shareholders' meeting is the company's highest authority, responsible for electing directors, approving financial reports, and making significant corporate decisions [46][47] - Ordinary resolutions require a simple majority, while special resolutions require at least two-thirds of the votes [80][82] Meeting Procedures - The company must notify shareholders of meetings at least 20 days in advance for annual meetings and 15 days for temporary meetings [60][61] - The meeting records must be kept for at least ten years, documenting all proceedings and decisions made [78]

Financial Overview - The total revenue for the first half of 2025 is CNY 1,264,512,369.54, a decrease from CNY 1,679,430,180.36 in the same period of 2024, representing a decline of approximately 24.7% [5] - The total operating costs for the first half of 2025 amount to CNY 1,099,775,216.97, down from CNY 1,488,288,264.61 in 2024, indicating a reduction of about 26.1% [5] - The net profit for the first half of 2025 is CNY 153,521,724.04, compared to CNY 204,088,697.72 in 2024, reflecting a decrease of approximately 24.8% [5][6] Assets and Liabilities - Total assets at the end of the first half of 2025 are CNY 5,025,993,962.59, down from CNY 5,211,440,858.19 at the beginning of the year [2][3] - Total liabilities decreased to CNY 1,178,361,326.43 from CNY 1,263,509,520.45, showing a reduction of about 6.7% [3][4] - Total equity stands at CNY 3,847,632,636.16, down from CNY 3,947,931,337.74, indicating a decrease of approximately 2.5% [3][4] Cash Flow - The net cash flow from operating activities for the first half of 2025 is CNY 213,061,017.36, a significant improvement compared to a negative cash flow of CNY -232,303,029.43 in the same period of 2024 [7] - Cash flow from investing activities shows a net outflow of CNY -282,971,008.20, compared to a net inflow of CNY 31,953,340.29 in 2024 [7] - Cash flow from financing activities resulted in a net outflow of CNY -229,507,233.21, compared to a net outflow of CNY -125,322,678.53 in the previous year [9] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 are both CNY 0.1699, down from CNY 0.2399 in the same period of 2024 [6][7]

证券代码：000989 证券简称：九芝堂 公告编号：2025-060 主管会计工作的负责人： 周鲁宝 会计机构负责人：周鲁 宝 法定代表人：王立峰 ...

Core Points - The document outlines the rules for the shareholders' meeting of JiuZhiTang Co., Ltd, ensuring compliance with relevant laws and regulations [2][3][25] - The rules specify the procedures for convening, proposing, notifying, and conducting shareholders' meetings [2][5][11] Group 1: General Provisions - The rules are established to regulate the behavior of JiuZhiTang Co., Ltd and ensure shareholders can exercise their rights legally [2] - The company must strictly follow laws, regulations, and its articles of association when convening shareholders' meetings [3][4] Group 2: Convening Shareholders' Meetings - Shareholders' meetings can be annual or temporary, with annual meetings held within six months after the end of the previous fiscal year [5] - Temporary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [5][6] Group 3: Proposals and Notifications - Shareholders holding more than 1% of shares can propose temporary proposals ten days before the meeting [9] - Notifications for annual meetings must be sent at least twenty days in advance, while temporary meetings require a fifteen-day notice [16][19] Group 4: Conducting Shareholders' Meetings - Meetings should be held at the company's registered location, and provisions must be made for remote participation [11][12] - The meeting must be presided over by the chairman or a designated representative, ensuring order and addressing shareholder inquiries [28][30] Group 5: Voting and Resolutions - Voting can be conducted in person or through remote means, with each share carrying one vote [24][26] - Resolutions require a simple majority for ordinary decisions and a two-thirds majority for special resolutions [44][46] Group 6: Record Keeping and Compliance - Meeting records must include details such as time, location, attendees, and voting results, and must be preserved for at least ten years [42][43] - The rules are subject to interpretation by the board and must comply with national laws and regulations [25][53]

公司营业总收入为12.65亿元，较去年同报告期营业总收入减少4.15亿元，同比较去年同期下降 24.71%。归母净利润为1.44亿元，较去年同报告期归母净利润减少6077.21万元，同比较去年同期下降 29.71%。经营活动现金净流入为2.13亿元，较去年同报告期经营活动现金净流入增加4.45亿元。 公司股东户数为5.05万户，前十大股东持股数量为4.38亿股，占总股本比例为51.19%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | | 黑龙江辰能工大创业投资有限公司 | 24.04% | | AWNH | 李振国 湖南益丰医药有限公司 | 18.91% 4.99% | | | 吕良幸 | 0.74% | | 5 | 兰建勋 | 0.65% | | 6 周晶 | | 0.63% | | 7 | 刘鹏俊 | 0.44% | | 8 | 陶永玲 | 0.28% | | 9 徐旭 | | 0.27% | | 10 | 基本养老保险基金一二零七组合 | 0.25% | 公司摊薄每股收益为0.17元，较去年同报告期摊薄每股收益减少0.07元，同比较去年 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, attributed to various external and internal factors affecting sales performance [1] Financial Performance - The company achieved a revenue of 1.265 billion yuan in the first half of 2025, representing a year-on-year decrease of 24.71% [1] - The net profit attributable to shareholders was 144 million yuan, down 29.71% compared to the same period last year [1] Factors Influencing Performance - The decline in sales revenue is attributed to a combination of external environmental factors, market conditions, and short-term adjustments due to internal reforms [1]

格隆汇8月20日丨九芝堂(000989.SZ)公布2025年半年度报告，上半年公司实现营业收入12.65亿元，同比 下降24.71%；归属于上市公司股东的净利润1.44亿元，同比下降29.71%；归属于上市公司股东的扣除非 经常性损益的净利润1.36亿元，同比下降28.45%；基本每股收益0.1699元。 ...

Group 1 - The core viewpoint of the news is that Jiuzhitang Co., Ltd. has shown significant financial growth and advancements in its research and development projects during the first half of 2025, following a change in its controlling shareholder and leadership [1][2][3] - Jiuzhitang reported a revenue of 1.265 billion yuan and a net profit attributable to shareholders of 144 million yuan, with operating cash flow increasing by 191.72% compared to the same period last year [1] - The company has made progress in its organizational structure optimization, marketing reforms, and accelerated innovation in R&D, particularly in its stem cell projects and new drug candidates YB209 and YB211 [1][2] Group 2 - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed the development and validation of immunogenicity research methods and is nearing the end of Phase I clinical trials [1] - The YB211 project, a new cyclic lipopeptide antibiotic targeting drug-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled so far [1][2] - Jiuzhitang's subsidiary, Beijing Meike, has completed the enrollment of all 45 subjects in the Phase IIa clinical trial for stem cell treatment of ischemic stroke and has received approval for a clinical trial on autism treatment [2][3] Group 3 - Beijing Meike is exploring the application of stem cell therapy in more disease areas and has established a large-scale stem cell drug R&D production base compliant with GMP standards in China, the US, and the EU [3] - Jiuzhitang is actively investing in the development of new traditional Chinese medicine products and conducting real-world studies on existing key products, including the classic Chinese medicine formulas YB106 and YB107 [3] - The company aims to clarify the advantageous treatment areas of its key products through evidence-based research, supporting the upgrade of its traditional Chinese medicine varieties and fostering the development of major products [3]

Group 1 - The company achieved a revenue of 1.265 billion yuan and a net profit of 144 million yuan in the first half of 2025, with operating cash flow increasing by 191.72% compared to the same period last year [2] - The company is actively engaged in innovation and research, making significant progress in the fields of innovative drugs and stem cells [2] - The new major shareholder, Heilongjiang Provincial State-owned Assets Supervision and Administration Commission, took control of the company in January 2023, and a new chairman was appointed in July 2023 [2] Group 2 - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed method development and verification for immunogenicity research, with Phase I clinical trials nearing completion [2] - The YB211 project, targeting antibiotic-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled [2] - The company’s subsidiary, Beijing Meike, has completed enrollment for clinical trials on stem cell treatments for ischemic stroke and autoimmune pulmonary alveolar proteinosis [3] Group 3 - Beijing Meike has received approval for clinical trials using stem cells to treat autism, expanding the application prospects of its stem cell technology [3][4] - The company is also advancing the development of traditional Chinese medicine, with ongoing research on classic formulas and real-world studies for several key products [4] - The real-world study for the product Shuxuetong injection has registered 2,141 cases, and various other key products are undergoing clinical evidence-based research [4]